• Nicotine Signaling Accelerates CKD Progression via ROS and n

  2026-06-22

  Jain and Jaimes' study establishes nicotine as a central mediator in the progression of chronic kidney disease (CKD) among smokers, identifying renal nicotinic acetylcholine receptor activation and oxidative stress as key mechanisms. This review clarifies the pathological interplay between nicotine exposure, reactive oxygen species, and renal fibrosis, highlighting new targets for translational intervention.

• PMS Activates GPR30/PI3K/AKT to Promote Osteoblastic Activit

  2026-06-21

  This study establishes that the PMS combination—psoralen, magnoflorine, and sweroside—enhances osteoblastic activity and counters osteoporosis by activating the GPR30/PI3K/AKT pathway. The findings clarify a novel mechanism for traditional Chinese medicine components in bone health and offer actionable routes for estrogen signaling research.

• Tamsulosin in Urological Research: Protocols and Applied Ins

  2026-06-20

  Tamsulosin, a selective α₁A-adrenergic receptor antagonist, transforms urological research workflows by delivering robust, reproducible smooth muscle relaxation and stone expulsion models. This article translates clinical and bench research into actionable protocols, troubleshooting insights, and key innovations for scientists leveraging APExBIO’s Tamsulosin.

• Apicidin as a Histone Deacetylase Inhibitor: Applied Bench W

  2026-06-19

  Apicidin, a selective histone deacetylase inhibitor, empowers researchers to dissect chromatin regulation, probe cancer biology, and evaluate reproductive toxicity. This article unpacks optimized workflows, troubleshooting strategies, and critical insights from the latest reference studies to maximize experimental reproducibility and interpretability.

• SmD2 Acetylation, Spliceosome Regulation, and HDAC Inhibitio

  2026-06-19

  This study uncovers how acetylation-dependent regulation of the core spliceosome protein SmD2 controls alternative splicing and DNA repair in hepatocellular carcinoma (HCC). The authors demonstrate that targeting HDAC2-mediated deacetylation of SmD2 with Romidepsin sensitizes HCC cells to PARP inhibition, suggesting a combinatorial therapeutic strategy for BRCA-wildtype tumors.

• Escitalopram in Translational Research: Precision, Selectivi

  2026-06-18

  Explore the scientific precision and translational value of Escitalopram (Lexapro) as a selective serotonin reuptake inhibitor for antidepressant research. This article delves into advanced mechanistic insights, assay design implications, and experimental limitations to guide neuroscience investigators.

• Anti-Fibrotic Potential of 1-Phenyl-2-Pentanol in Hepatic St

  2026-06-18

  This study presents a detailed in vitro evaluation of 1-Phenyl-2-Pentanol, a compound from Moringa oleifera leaves, as an inhibitor of hepatic stellate cell activation and liver fibrosis progression. By integrating proteomics and functional assays, the authors identify modulation of TGF-β1 and Wnt/β-catenin signaling as key mechanisms, expanding the repertoire of natural products with anti-fibrotic properties.

• Mubritinib (TAK 165): Optimizing Complex I Inhibition in Onc

  2026-06-17

  Mubritinib (TAK 165) redefines mitochondrial complex I inhibition with nanomolar precision, selectively targeting chemotherapy-resistant AML and KSHV-driven PEL cells. This article delivers actionable protocols, troubleshooting guidance, and translational strategies, backed by the latest mechanistic insights and cross-domain utility.

• Refining In Vitro Cancer Drug Response: Insights from Viabil

  2026-06-17

  Schwartz's dissertation introduces a nuanced framework for evaluating anticancer drug responses in vitro by distinguishing between growth inhibition and cell death through separate viability metrics. This approach clarifies how drugs like Wee1 kinase inhibitors exert their effects, informing assay design and interpretation across cancer research. The work provides actionable guidance for researchers employing cell cycle checkpoint abrogation strategies.

• Sulfur Transport Regulates Nodule Senescence in Soybean

  2026-06-16

  A recent study demonstrates that sulfur supply to the symbiosome delays nodule senescence in soybean by maintaining glutathione levels and controlling reactive nitrogen species. These findings provide mechanistic insight into the nutrient regulation of symbiotic nitrogen fixation and offer strategies to enhance legume productivity and reduce reliance on chemical fertilizers.

• Applied Use-Cases of PPM-18 in iNOS and NF-κB Pathway Inhibi

  2026-06-16

  PPM-18 (N-(1,4-dihydro-1,4-dioxo-2-naphthalenyl)-benzamide) stands out for its precision in iNOS and NF-κB pathway inhibition, enabling robust inflammation and sepsis model studies. Discover workflow refinements, troubleshooting strategies, and advanced applications that leverage APExBIO’s high-purity compound for reproducible and translational research.

• LMO2–LDB1 Complex: Mechanistic Driver in AML Progression

  2026-06-15

  This study delineates how the interaction between LMO2 and the transcriptional co-regulator LDB1 drives acute myeloid leukemia (AML) cell proliferation and survival. By integrating genetic, proteomic, and functional genomics analyses, the paper identifies the LMO2/LDB1 complex as a potential therapeutic target in AML and clarifies its mechanistic contribution to leukemogenesis.

• Novel HER2 Inhibitors Target Breast Cancer EMT: Insights vs.

  2026-06-15

  This study reports the synthesis and biological evaluation of new HER2 inhibitors, using a Mubritinib-derived scaffold, to suppress breast cancer cell migration through EMT pathway modulation. The research identifies a lead compound, Q7j, with superior anti-breast cancer activity compared to Mubritinib, offering new mechanistic perspectives for HER2-driven cancer research.

• Single-Nucleus RNA-Seq Reveals ATRNL1’s Role in Atrial Fibri

  2026-06-14

  This study deploys large-scale single-nuclei RNA sequencing to uncover cell-type-specific transcriptional changes in atrial fibrillation, identifying ATRNL1 as a key regulator in cardiomyocytes. The findings offer new molecular insight into AF pathogenesis and open avenues for targeted therapeutic research.

• RNA Pol II Inhibition Drives Apoptosis via Non-Transcription

  2026-06-13

  Harper et al. (2025) reveal that inhibition of RNA polymerase II triggers cell death not by passive mRNA loss, but through an active apoptotic signaling pathway initiated by the degradation of hypophosphorylated RNA Pol IIA. This mechanistic insight redefines how transcription-targeting therapies induce apoptosis and provides a new perspective for designing oncology research workflows.

454 records 14/31 page Previous Next First page 上5页 1112131415 下5页 Last page